Background:Current treatment options for human epidermal growth factor receptor 2(HER2)-overexpressing gastric cancer at third-line have shown limited clinical benefit.Further,there is no specific treatment for HER2 i...Background:Current treatment options for human epidermal growth factor receptor 2(HER2)-overexpressing gastric cancer at third-line have shown limited clinical benefit.Further,there is no specific treatment for HER2 immunohistochemistry(IHC)2+and fluorescence in-situ hybridization-negative patients.Here,we report the efficacy and safety of a novel anti-HER2 antibody RC48 for patients with HER2-overexpressing,advanced gastric or gastroesophageal junction cancer.Methods:Patients with HER2-overexpressing(IHC 2+or 3+),locally advanced or metastatic gastric or gastroesophageal junction cancer who were under at least second-line therapy were eligible and received RC482.5 mg/kg alone every 2 weeks.The primary endpoint was the objective response rate(ORR)assessed by an independent review committee.Secondary endpoints included progressionfree survival(PFS),overall survival(OS),duration of response,time to progression,disease control rate,and safety.Results:Of 179 patients screened,125 were eligible and received RC48 treatment.The ORR was 24.8%(95%confidence interval[CI]:17.5%-33.3%).The median PFS and OS were 4.1 months(95%CI:3.7-4.9 months)and 7.9 months(95%CI:6.7-9.9 months),respectively.The most frequently reported adverse events were decreased white blood cell count(53.6%),asthenia(53.6%),hair loss(53.6%),decreased neutrophil count(52.0%),anemia(49.6%),and increased aspartate aminotransferase level(43.2%).Serious adverse events(SAEs)occurred in 45(36.0%)patients,and RC48-related SAEs were mainly decreased neutrophil count(3.2%).Seven patients had adverse events that led to death were not RC48-related.Conclusions:RC48 showed promising activity with manageable safety,suggesting potential application in patients with HER2-overexpressing,advanced gastric or gastroesophageal junction cancer who have previously received at least two lines of chemotherapy.展开更多
In plants, photoperiod is an important cue for determining flowering. The floral transition in Arabidopsis thaliana is earlier under long-day （LD） than under short-day （SD） conditions. Flowering of Arabidopsis pla...In plants, photoperiod is an important cue for determining flowering. The floral transition in Arabidopsis thaliana is earlier under long-day （LD） than under short-day （SD） conditions. Flowering of Arabidopsis plants under SD conditions is mainly regulated by the plant hormone gibberellin （GA）. Here, we report two WRKY transcription factors function oppositely in controlling flowering time under SD conditions. Phenotypic analysis showed that disruption of WRKY12 caused a delay in flowering, while loss of WRKY13 function promoted flowering. WRKY12 and WRKY13 displayed negatively correlated expression profiles and function successively to regulate flowering. Molecular and genetic analyses demonstrated that FRUITFULL （FUL） is a direct downstream target gene of WRKY12 and WRKY13. Interestingly, we found that DELLA proteins GIBBERELLIN INSENSITIVE （GAI） and RGA-LIKE1 （RGL1） interacted with WRKY12 and WRKY13, and their interactions interfered with the transcriptional activity of the WRKY12 and WRKY13. Further studies suggested thatWRKY12 and WRKY13 partly mediated the effect of GA3 on controlling flowering time. Taken together, our results indicate that WRKY12 and WRKY13 oppositely modulate flower- ing time under SD conditions, which at least partially involves the action of GA.展开更多
基金This study was funded by RemeGen Co.,Ltd.This work was also supported by the National Natural Science Foundation of China(No.91959205)the Ministry of Science and Technology of China(No.2017YFC1308900,No.2018ZX09201-015)Beijing Municipal Health Commission(No.2020-1-1022)。
文摘Background:Current treatment options for human epidermal growth factor receptor 2(HER2)-overexpressing gastric cancer at third-line have shown limited clinical benefit.Further,there is no specific treatment for HER2 immunohistochemistry(IHC)2+and fluorescence in-situ hybridization-negative patients.Here,we report the efficacy and safety of a novel anti-HER2 antibody RC48 for patients with HER2-overexpressing,advanced gastric or gastroesophageal junction cancer.Methods:Patients with HER2-overexpressing(IHC 2+or 3+),locally advanced or metastatic gastric or gastroesophageal junction cancer who were under at least second-line therapy were eligible and received RC482.5 mg/kg alone every 2 weeks.The primary endpoint was the objective response rate(ORR)assessed by an independent review committee.Secondary endpoints included progressionfree survival(PFS),overall survival(OS),duration of response,time to progression,disease control rate,and safety.Results:Of 179 patients screened,125 were eligible and received RC48 treatment.The ORR was 24.8%(95%confidence interval[CI]:17.5%-33.3%).The median PFS and OS were 4.1 months(95%CI:3.7-4.9 months)and 7.9 months(95%CI:6.7-9.9 months),respectively.The most frequently reported adverse events were decreased white blood cell count(53.6%),asthenia(53.6%),hair loss(53.6%),decreased neutrophil count(52.0%),anemia(49.6%),and increased aspartate aminotransferase level(43.2%).Serious adverse events(SAEs)occurred in 45(36.0%)patients,and RC48-related SAEs were mainly decreased neutrophil count(3.2%).Seven patients had adverse events that led to death were not RC48-related.Conclusions:RC48 showed promising activity with manageable safety,suggesting potential application in patients with HER2-overexpressing,advanced gastric or gastroesophageal junction cancer who have previously received at least two lines of chemotherapy.
文摘In plants, photoperiod is an important cue for determining flowering. The floral transition in Arabidopsis thaliana is earlier under long-day （LD） than under short-day （SD） conditions. Flowering of Arabidopsis plants under SD conditions is mainly regulated by the plant hormone gibberellin （GA）. Here, we report two WRKY transcription factors function oppositely in controlling flowering time under SD conditions. Phenotypic analysis showed that disruption of WRKY12 caused a delay in flowering, while loss of WRKY13 function promoted flowering. WRKY12 and WRKY13 displayed negatively correlated expression profiles and function successively to regulate flowering. Molecular and genetic analyses demonstrated that FRUITFULL （FUL） is a direct downstream target gene of WRKY12 and WRKY13. Interestingly, we found that DELLA proteins GIBBERELLIN INSENSITIVE （GAI） and RGA-LIKE1 （RGL1） interacted with WRKY12 and WRKY13, and their interactions interfered with the transcriptional activity of the WRKY12 and WRKY13. Further studies suggested thatWRKY12 and WRKY13 partly mediated the effect of GA3 on controlling flowering time. Taken together, our results indicate that WRKY12 and WRKY13 oppositely modulate flower- ing time under SD conditions, which at least partially involves the action of GA.
